scholarly journals Reproductive Health and Vitamin D

2021 ◽  
Vol 5 (1) ◽  
pp. 36-42
Author(s):  
Nafiye KARAKAŞ YILMAZ ◽  
Banu SEVEN
2016 ◽  
Vol 22 (4) ◽  
pp. 28 ◽  
Author(s):  
S. Yu. Kalinchenko ◽  
M. I. Zhilenko ◽  
D. A. Gusakova ◽  
I. A. Tjuzikov ◽  
G. Zh. Mshalaja ◽  
...  

2016 ◽  
Vol 34 (02) ◽  
pp. e1-e13 ◽  
Author(s):  
Aya Mousa ◽  
Sally Abell ◽  
Robert Scragg ◽  
Barbora Courten

2017 ◽  
pp. 46-47
Author(s):  
O. I. Yazykova ◽  
E. G. Khilkevich

Study objective. To study the efficacy of the drugs vitamin D at the stage of planning of pregnancy in women with infertility of various etiologies, according to domestic and foreign literature.Materials and methods. We conducted a search of the literature sources by the keywords “vitamin D”, “infertility”, “pregravid preparation” in domestic and foreign databases: elibrary, Medline/PubMed, Embase, CINAHL. 23 sources were selected.Study results. Vitamin D plays an important role in the regulation of the menstrual cycle and the reproductive health of women. The prevalence of vitamin D deficiency among women with infertility of various etiologies reaches 69%. It is vital to achieve an adequate level of vitamin D in a woman’s body and to prevent its deficiency.Conclusion. For all women with infertility at the stage of preparation it is recommended to conduct assessment of adequacy of vitamin D by determination of 25(OH)D in serum and correction of its deficit to achieve levels of 25(OH)D more than 30 ng/ml. 


2018 ◽  
Vol 0 (41) ◽  
pp. 84-94
Author(s):  
Т. Ф Татарчук ◽  
К. Д. Дейнюк ◽  
О. В. Занько ◽  
Т. І. Юско ◽  
В. О. Тарнопольська

2021 ◽  
Vol 3_2021 ◽  
pp. 189-195
Author(s):  
Artymuk N.V. Artymuk ◽  
Tachkova O.A. Tachkova ◽  

2020 ◽  
Vol 10_2020 ◽  
pp. 174-181
Author(s):  
Maltseva L.I. Maltseva ◽  
Garifullova Yu.V. Garifullova ◽  
Yupatov Е.Yu. Yupatov ◽  
◽  

Nutrients ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1489 ◽  
Author(s):  
Melinda Fernando ◽  
Stacey J. Ellery ◽  
Clara Marquina ◽  
Siew Lim ◽  
Negar Naderpoor ◽  
...  

Vitamin D-binding protein (VDBP), the main carrier of vitamin D, has recently been implicated in reproductive health and pregnancy outcomes including endometriosis, polycystic ovary syndrome (PCOS), pre-eclampsia, and gestational diabetes mellitus (GDM). Improved methods for measuring VDBP and an increased understanding of its role in biological processes have led to a number of newly published studies exploring VDBP in the context of pregnancy. Here, we synthesize the available evidence regarding the role of VDBP in reproductive health and pregnancy, and we highlight areas requiring further study. Overall, low levels of maternal serum VDBP concentrations have been associated with infertility, endometriosis, PCOS and spontaneous miscarriage, as well as adverse pregnancy outcomes including GDM, pre-eclampsia, preterm birth and fetal growth restriction. However, increased VDBP concentration in cervicovaginal fluid has been linked to unexplained recurrent pregnancy loss and premature rupture of membranes. Some genetic variants of VDBP have also been associated with these adverse outcomes. Further studies using more accurate VDBP assays and accounting for ethnic variation and potential confounders are needed to clarify whether VDBP is associated with reproductive health and pregnancy outcomes, and the mechanisms underlying these relationships.


2020 ◽  
pp. 268-273
Author(s):  
I. G. Zhoukovskaya ◽  
I. R. Yakupova

The article presents the results of a study of the effect of vitamin D deficiency on women’s health.The study aimed to determine the prevalence of vitamin D deficiency and its relationship with the somatic and reproductive health of women.Methods: observation group I included 31 women with a reduced serum vitamin D levels (20.4 ± 1.0 ng/ml), comparison group II included 31 patients with normal vitamin D levels (39.0 ± 1.4 ng/ml). Results: the negative effect of vitamin D deficiency on women’s health is also practically assured, i.e. the incidence of somatic pathology is significantly higher in group I compared with group II: obesity (62.5 ± 12.1% and 18.8 ± 9.8%; p <0.5), insulin resistance (55.0 ± 9.0% and 1.0 ± 6.0%; p <0.001); arterial hypertension (42.0 ± 8.8% and 13.0 ± 6.0%; p <0.01); hypertrophic myocardiopathy (25.8 ± 7.8% and 6.4 ± 4.4%; p <0.05); chronic colitis (29.0 ± 8.1% and 6.4 ± 4.4%; p <0.05), gastric ulcer (22.5 ± 7.5% and 3.2 ± 3.2%; p <0.05), chronic pancreatitis (22.5 ± 7.5% and 3.2 ± 3.2%; p <0.05), chronic gastritis (25.8 ± 7.8% and 9.7 ± 5.3%; p <0.1). The interaction between reduced vitamin D levels and reproductive system diseases is confirmed by significant increase in the prevalence of secondary amenorrhea (80.0 ± 9.0% and 16.0 ± 7.3%; p <0.001), secondary oligomenorrhea (75.0 ± 9.7% and 20.0 ± 8.0%; p <0.001), hyperplastic processes – uterine fibroids (48.4 ± 9.0% and 13.3 ± 6.1%; p <0.001) and adenomyosis (26.6 ± 7.9% and 6.7 ± 4.5%; p <0.05), polycystic ovary syndrome (29.0 ± 8.2% and 6.7 ± 4.5%; p <0.05), vaginal microbiocenosis disorders (aerobic vaginitis – 42.0 ± 8.9% and 16.1 ± 6.6%; p <0.05; bacterial vaginosis – 29.0 ± 8.2% and 9.7 ± 5.3%; p <0.05).Conclusion: management of vitamin D level is one of the priorities in the formation of therapeutic and preventive measures to improve the women’s health.


Sign in / Sign up

Export Citation Format

Share Document